Market Overview

Benzinga's Top #PreMarket Gainers

Related SNTA
Morning Market Losers
Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer
Premarket Biotech Digest: FibroGen's Gains, Anavex Data, Geron Rallies (Seeking Alpha)
Related ISR
IsoRay's Cesium-131 Cancer Fighting Portfolio was on Display at the American Association of Physicists in Medicine (AAPM) Convention
Morning Market Gainers

Synta Pharmaceuticals (NASDAQ: SNTA) surged 30.53% to $6.20 in the pre-market session on positive interim results from the ENCHANT-1 trial of ganetespib in metastatic breast cancer.

Sinovac Biotech (NASDAQ: SVA) shares gained 8.85% to $7.50 in the pre-market after the company reported unaudited Q4 results. Sinovac Biotech posted its quarterly net income of $5.8 million, or $0.10 per share, versus a year-ago net loss of $4.6 million, or $0.08 per share.

IsoRay (NYSE: ISR) surged 7.45% to $2.74 in pre-market trading as the company announced first pediatric Cesium-131 seeded mesh treatment for metastatic Wilms tumor.

Novavax (NASDAQ: NVAX) shares jumped 7% to $5.50 in pre-market trading after falling 4.10% on Wednesday.

Posted-In: PreMarket GainersNews Pre-Market Outlook Markets Movers


Related Articles (ISR + NVAX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters